



# ACNP Bulletin

American College of Neuropsychopharmacology 545 Mainstream Drive, Suite 110, Nashville, TN 37228-1201  
Tel: 615-324-2360 • Fax: 615-324-2361 • E-mail: [acnp@acnp.org](mailto:acnp@acnp.org) • [www.acnp.org](http://www.acnp.org)

November 2006

Volume 12, Issue 4

## In this issue:

NPP Reviews 1

Preliminary Program 2  
and Meeting  
Information

Rapid Publication 3

Post Marketing Drug 3  
Surveillance Meeting

Announcements 4

COI Policy 5

Secretary Report/ 6  
Strategic Plan  
Report Preview

Upcoming Meetings 7

## Neuropsychopharmacology Reviews Series Editors Named

### Sam Enna

Chair, Publications Committee

The ACNP Publications Committee has appointed Peter Kalivas and Husseini Manji as Series



Husseini Manji

Editors for *Neuropsychopharmacology Reviews (NPP Reviews)*. They will compliment each other well as they launch this new annual review publication. The Series Editors have already begun to work on the many tasks before them, including recruiting Volume Editors and Authors and developing the subject matter and overall guidelines for this publication. Peter and Husseini have set an ambitious goal to have the first volume of *NPP Reviews* ready to distribute to the members at the 2007 ACNP Annual Meeting. In order to accomplish this they will serve as the Volume Editors for the initial volume. As always, we welcome your input and I know that Peter and Husseini will appreciate your advice and your support.



Peter Kalivas

The primary audience for this new publication will be clinical investigators and neuroscientists actively engaged in research related to neuropsychopharmacology. However, authors will be encouraged to prepare the work so as to be informative to practicing physicians and interested lay readers as well. Each article will be a comprehensive review of the topic, containing summary tables, figures, and an extensive list of references. An effort will be made to provide a mix of articles each year covering topics of importance to clinical and basic neuroscientists. However, emphasis will be placed on recruiting authors to cover subjects the editors deem of greatest and most immediate interest and importance to the field. While the aim would be to provide coverage of topics on all aspects of clinical and basic neuropsychopharmacology every five to seven years, no limits will be placed on how often aspects of a particular subject may be reviewed since selection of material for coverage will be driven, in part, by events and the effort to keep the work topical.

The ACNP Publications Committee has also reviewed proposals from a number of publishers, and as this is being written, is currently in negotiations with Nature Publishing Group (NPG) to serve as publisher. As the current publisher of *Neuropsychopharmacology*, NPG has done a great job for the journal and we believe they offer a number of advantages over their competitors by making this new publication an extension of the journal.

## Annual Meeting Information

**Annual meeting badges** are currently being sent to each registered attendee. Please watch your mailbox and bring your badge to the meeting to reduce your wait time during registration. If you do not bring your badge to the meeting, you will be required to provide identification at registration.

**Posters:** Please be reminded—in order to hang your poster at this year's meeting, you will need **push pins or tacks**; they will not be provided.

**Wireless access** will be provided throughout the lobby of the meeting area, outside the ballroom and session rooms. Please feel free to bring your laptop to have full access.

**The Networking meeting** for spouses and accompanying others will be held on Monday, December 4, 2006, 6:30 pm - 7:30 pm. This year, this session is in conjunction with the showing of a the movie **West 47th Street** from 7:30 pm - 9:30 pm. A film produced and directed by Bill Lichtenstein and June Peoples, this documentary follows four people with mental illness, off the streets and out of homeless shelters, in and out of the hospital, at home and work, over the course of three years.

**Itinerary Planner:** Please be sure to visit the itinerary planner at [acnp.abstractcentral.com](http://acnp.abstractcentral.com).

**Program Book** will be available online in advance of the meeting at [www.acnp.org](http://www.acnp.org).

**Meeting Evaluation:** All meeting attendees are urged to complete an evaluation of the meeting. Attendees who are requesting CME credit for the meeting **are required** to complete the evaluation. The cost for CME credits is \$40.00. You may complete the evaluation in the ACNP Computer Center in Diplomat 4 or on-line at [www.acnp.org](http://www.acnp.org) (click on Annual Meeting link). All evaluations must be completed by January 15, 2007.

**Registration Rates** for the Annual Meeting increased on November 10, 2006.

**Restaurant Guide:** Please be sure to pick up your restaurant guide in the Service Center or on the display table outside the Grand Ballroom.

**KNOW BEFORE YOU GO!** Before you leave for the ACNP Annual Meeting in Hollywood, be sure you are fully informed on the current travel allowances and restrictions at your home city's airport. To get the most up-to-date information, go to [www.tsa.gov](http://www.tsa.gov) or you can call them at 1-866-289-9673.

**Opening Night Reception:** Please be reminded the Buffet Reception this year will be on Sunday evening from 8:00 pm - 10:00 pm instead of the usual closing Thursday night reception. Please join your colleagues at The Westin Diplomat Resort & Spa Infinity Pool Deck overlooking the Atlantic Ocean for an evening of Latin music and dancing. Music will be provided by the Mambo Kings and entertainment will be provided by a show of Sizzling Latin dancers.

### ACNP Service Center

Sunday-Wednesday 7:30 am - 5:00 pm  
Thursday 7:30 am - 12:00 pm

### Computer Center

Sunday-Wednesday 7:30 am - 9:00 pm  
Thursday 7:30 am - 5:00 pm

## PRELIMINARY SCHEDULE – 45th ANNUAL MEETING

The Westin Diplomat, Hollywood, Florida  
DECEMBER 3-7, 2006

### Saturday, December 2, 2006

8:00 am - 3:00 pm Council Meeting  
8:30 am - 3:30 pm Committee Meetings as called by chairs  
10:00 am - 6:00 pm Registration  
6:30 pm - 7:30 pm Travel Award Reception

### Sunday, December 3, 2006

7:00 am - 8:15 am Travel Award Breakfast  
7:30 am - 5:00 pm Registration  
8:30 am - 12:30 pm Teaching Day  
1:00 pm - 2:30 pm Teaching Neuropsychopharmacology  
2:30 pm - 5:00 pm Paper Sessions: "Hot Topics"  
5:15 pm - 7:45 pm Pioneer Symposium  
8:00 pm - 10:00 pm Opening Reception

### Monday, December 4, 2006

7:30 am - 5:00 pm Registration  
8:30 am - 12:00 pm President's Plenary  
10:30 am - 4:30 pm Poster Viewing  
12:00 pm - 1:30 pm Buffet Lunch  
1:30 pm - 2:45 pm Distinguished Lecture  
3:00 pm - 5:30 pm Panel Sessions  
5:30 pm - 7:30 pm Poster Session I with Reception  
7:30 pm - 9:00 pm Issue Oriented Study Groups

### Tuesday, December 5, 2006

7:30 am - 5:00 pm Registration  
8:30 am - 11:00 am Panel Sessions  
10:30 am - 4:30 pm Poster Viewing  
11:00 am - 12:30 pm Lunch  
11:00 am - 12:30 pm Code of Conduct for Supporting Corp lunch  
12:30 pm - 3:00 pm Issues in Ethics  
3:00 pm - 5:30 pm Panel Sessions  
5:30 pm - 7:30 pm Poster Session II with Reception  
6:00 pm - 11:00 pm Council Meeting for Committee Reports

### Wednesday, December 6, 2006

8:00 am - 5:00 pm Registration  
8:30 am - 11:00 am Panel Sessions  
10:30 am - 4:30 pm Poster Viewing  
11:15 am - 12:30 pm Business Meeting (Members Only)  
12:30 pm - 1:45 pm Buffet Lunch  
12:30 pm - 2:30 pm Travel Award Luncheon  
3:00 pm - 5:30 pm Panel Sessions  
5:30 pm - 7:30 pm Poster Session III with Reception

### Thursday, December 7, 2006

8:00 am - 3:00 pm Registration  
8:30 am - 11:00 am Panel Sessions  
11:30 am - 1:30 pm Council Meeting  
3:00 pm - 5:30 pm Panel Sessions

## ACNP Rapid Publication Website

The ACNP Rapid Publication website was originally created in 2000 in order to make accepted manuscripts quickly available in a citable fashion to the scientific community. At that time, this was a new and innovative concept, but things have changed dramatically since then. At the time we initiated this venture, our lag time to print publication was up to eight months and papers were not available during that time. Now, through our publisher's Advance Online Publication, a final copyedited and citable PDF text is posted online with an average of about 40 days. Therefore, we are no longer posting accepted manuscripts on our Rapid Publication website. If you have any questions, please contact the ACNP office at [acnp@acnp.org](mailto:acnp@acnp.org).

## Human Research Committee Convenes Meeting on Post Marketing Drug Surveillance

The ACNP convened a meeting on September 13, 2006, to assert the need for a new drug surveillance system in the U.S. Participants in the meeting concluded that to improve patient safety and reduce adverse events due to prescription drug use, the U.S. needs to create a system that tracks prescriptions linked to adverse events.

"The current U.S. health care system only accidentally detects rare but serious harmful effects of prescription medications, including legal off-label use of drugs prescribed for illnesses that were not studied in pre-marketing trials, as well as toxic drug interactions," said Charles P. O'Brien, M.D., Ph.D., Chair of ACNP's Human Research Committee. "Systematic prospective data collected through a computerized monitoring system could detect possible adverse events, serve as an early warning system, and better protect the public."

The meeting outlined three specific areas to explore. First, the implementation of "provisional approval" from FDA to allow drugs to come to market sooner while restricting the level of marketing that accompanies them. "This type of program will enable the people who need the drugs the most to get them while encouraging industry to continue to collect data and monitor side effects," said O'Brien.

Second, the computerized surveillance system needs to integrate medical records and pharmacy records to adequately research side effects. "A computerized database linked to a person's medical records will reduce medical errors and help physicians identify side effects that weren't detected during clinical trials," said Donald F. Klein, M.D.

Finally, ACNP should consider establishing fellowships in pharmacoepidemiology to promote the field and facilitate training. The group agreed that individuals with solid methodological expertise will be essential to collecting data and using it wisely.

The potential adaptation of a computerized cross-linked surveillance system similar to one used in the Netherlands known as PHARMO and the one used at the Department of Veterans Affairs were also reviewed during the meeting.

The key components of the PHARMO Institute system include practitioner, hospital, pharmacy, and laboratory records. Whether such a system is feasible in the United States was critically discussed. Possibilities include large health management organizations (HMOs) and federally-financed systems such as the Veterans Administration, Medicare, and Armed Services.

Recent high profile cases stirred public concern about drug safety and the effectiveness of the current monitoring system. Clinical trials conducted before the FDA approval of a pharmaceutical drug for a particular illness do identify many potential adverse reactions or complications for the medication. However, these clinical trials:

- Select patients who may be healthier than real-life patients and who may also receive better than average care.
- Usually last only a few months and include 500 to 3,000 individuals – these trials are too small and too short to identify rare or late events. However, larger or longer studies would delay useful drugs from coming to market.

In addition, concern about adverse effects detected after marketing is realistic since, even under the present system:

- 51% of drugs have label changes because of major safety issues discovered after marketing.
- 20% of drugs receive new black box warnings after marketing.
- 3% to 4% of drugs are ultimately withdrawn for safety reasons.

There is common mismanagement of prescription drugs or the use of prescription drugs for purposes other than the FDA-approved indication, posing serious challenges in patient safety since there is little relevant trial data.

These abrupt or seemingly late warnings about prescription drug use create uncertainty and fear among health care consumers trying to choose a correct course of treatment for themselves or their loved ones.

"Early recognition of possible harmful effects of prescription drug use is critical to improving patient health and safety in the US," added Klein. "It is our hope that this meeting will call attention to making more effective our system of monitoring the effects of marketed drugs."

## ACNP Directory

Please remember to update your information for the **ACNP Directory**. Information regarding this was sent via email on October 26, 2006. If you have any changes in address please return them to the ACNP office at [acnp@acnp.org](mailto:acnp@acnp.org). The annual ACNP Directory will be available in March 2007.

**ANNOUNCEMENT**  
**YOUNG INVESTIGATOR AWARD**  
July 1, 2007 to June 30, 2009

**THE PAUL JANSSEN FELLOWSHIP IN  
TRANSLATIONAL NEUROSCIENCE RESEARCH  
AT COLUMBIA UNIVERSITY**

Preliminary/Open Application Period: September 1 - December 1, 2006  
Funding Notification Date: February 2, 2007  
Fellowship Start Date: July 1, 2007

The Paul Janssen Fellowship is awarded to an outstanding young physician-investigator to conduct novel translational research in the field of neuroscience as it relates to psychiatric disease and medicine. The Paul Janssen Fellow will be assigned both a basic scientist mentor and a clinical investigator mentor from the faculty at Columbia University to serve as joint mentors. The fellow will take a basic observation made by the basic science mentor and apply it to the study of disease or treatment with the clinical research mentor.

**Eligibility:** Candidates from the international neuroscience community, holding an M.D. or M.D. and Ph.D. degrees, and preferably having completed initial fellowship research training, are invited to apply. Fellows at Columbia University or the New York State Psychiatric Institute/RFMH are encouraged to submit applications.

**Funding:** The award provides a stipend, commensurate with experience, as well as some funding for research costs. The stipend provided may require supplemental funding by the mentors.

Length of Fellowship: Up to two years.

**Preliminary Application Process** (to be submitted by December 1, 2006): The following should be provided in 12 point font (or larger) with a minimum of one-inch margins: 1) Face page letter identifying applicant and a brief description of previous training in medical research, previous research interests, current position and future research interests. 2) Front two-pages of the NIH biosketch (sections A & B only). 3) Letters of support/reference from at least three current or previous mentors. A complete project proposal is not required until notified.

Preliminary applications should be submitted electronically or via mail to:  
Renee Azima Heller, M.A.  
Administrator, The Paul Janssen Fellowship in Translational  
Neuroscience Research  
Division of Neuroscience/Department of Psychiatry  
Columbia University  
1051 Riverside Drive, Unit 42  
New York, NY 10032  
tel: (212) 543-6774 / fax: (212) 543-6017  
e-mail: rla2117@columbia.edu

**THE DECISION ON FINALISTS WILL BE MADE BY DECEMBER 15, 2006. IF YOU ARE SELECTED AS A FINALIST YOU WILL BE ASSIGNED A BASIC AND CLINICAL MENTOR AND WILL WORK WITH THEM TO COMPLETE YOUR APPLICATION BY SUBMITTING THE FOLLOWING (DUE BY JANUARY 12, 2007):**

1) A 150-word summary of proposed project. 2) Budget page specifying how funding will be allocated and describing the need and rationale for support at this point in the applicant's career. 3) One-half page statement of mentorship arrangements and training goals. 4) "Other Support" of current and pending funding indicating % effort and support level. 5) Research Plan (maximum of 5 pages): a. Goals; b. Background; c. Hypotheses; d. Experimental Design and Methods; e. Role of this study in awardee's plans for future research. 6) Letters of support from both mentors. 7) Signed statement by Department Chair demonstrating approval of project and responsibility for ensuring space, personnel, and facilities. IRB and/or IACUC approval for project must be provided before the Fellowship starts.

**ADAA CAREER DEVELOPMENT TRAVEL AWARDS**

**Submission Deadline: November 17, 2006**

The ADAA will give up to ten awards to individuals to attend and present a new research poster at the ADAA 27th Annual Conference March 29-April 1, 2007 at the Hyatt Regency in St. Louis, Missouri. These awards target new professionals with career interests in fields related to anxiety disorders, such as basic and clinical neuropsychopharmacology, clinical psychology, genetics, neuroimaging, and epidemiology. The goal of this award is to stimulate new investigators to pursue their work in the field of anxiety disorders and to familiarize them with the mission and activities of the ADAA.

Complimentary registration to the ADAA Annual Conference and the Scientific Satellite Research Symposium, March 29-April 1, 2007  
Complimentary one-year ADAA membership  
An award of \$1,000

**Eligibility:** Applicants must be Ph.D.-level scientists who have received their doctorates or completed a post-doctoral fellowship (whichever occurred last) within the past three years; or physician scientists who have completed their residency or research fellowship (whichever occurred last) within the past three years.

Applicants must be psychiatric residents or graduate students in neuroscience, psychology, social work or other related fields; they must have an interest in anxiety disorders and demonstrated previous relevant experience.

Candidates will be judged on the following points: evidence of commitment to the field of anxiety disorders, strength of training and current program, quality and extent of relevant research, and a personal statement and professional reference. Winners must attend and present a poster at the Annual Conference to receive the award.

**ADAA Junior Faculty Research Grants**

**Submission Deadline: December 15, 2006**

Provides two \$25,000\* one-year grants that are intended to provide partial salary support. The grants aim to increase the pool of independent investigators with interest and expertise in anxiety disorders research by assisting individuals in making the transition from trainee to junior faculty to independent investigator.

In addition, grantees will receive: a complimentary registration to ADAA's Annual Conference, and the invitation-only Scientific Meeting and Awards Luncheon in March 2007, a travel stipend of up to \$1,000 in order to attend the meeting; and a free one-year ADAA membership.

**Eligibility:** Applicants who have completed at least one year of a post-doctoral fellowship or post-residency research training by the time the grant is awarded. Investigators who have achieved the academic level of associate professor (or equivalent), or who are recipients of NIH/NIMH "K" or R01 grants, are NOT eligible. Applicants must have a mentor or senior research collaborator who is an established investigator in anxiety disorders research. Applications may cover a broad range of topics, including clinical, epidemiological, basic science and health policy-related research, but they must contribute to the understanding of and/or treatment for anxiety disorders. **Special consideration will be given to those applicants whose research with their affiliated institution is dependent on outside funding sources.**

\*Note: The ADAA does NOT pay institutional overhead on the Junior Faculty Research Grants.

**If you have questions about any of the award programs offered by the association, please call (240) 485-1031.**

**ANNOUNCEMENT**  
**National Sleep Foundation**  
**PICKWICK POSTDOCTORAL FELLOWSHIP**  
**Deadline: December 1, 2006**

The National Sleep Foundation (NSF) supports and encourages sleep research by offering the NSF **Pickwick Postdoctoral Fellowship** to persons interested in pursuing basic, clinical and applied sleep research.

NSF Pickwick Postdoctoral Fellows receive funding based on National Institutes of Health guidelines from \$36,996-\$45,048 plus a benefits allowance for two years, with the second year being contingent upon satisfactory progress. The deadline for the application is: December 1, 2006

Applicants may be non-US citizens, but to qualify for the NSF Pickwick Postdoctoral Fellowship, research must be conducted under the tutelage of a sleep mentor at an established American or Canadian laboratory.

Please share this with potential candidates, colleagues and others you think might be interested.

---

The 2007  
**Career Development Institute for Bipolar Disorder**  
*A Workshop on Launching and Maintaining a  
Career in Mental Health Research in Bipolar Disorder*  
**March 10-13, 2007**  
**Pittsburgh, Pennsylvania**



The 2007 Career Development Institute (CDI) for Bipolar Disorder, a workshop on launching and maintaining a career in mental health research in Bipolar Disorder, sponsored by the University of Pittsburgh, will be held in Pittsburgh, PA, March 10-13, 2007.

The aims of the CDI for Bipolar Disorder are to offer a broad-based group of junior investigators increased general knowledge of what a research career involves in academic psychiatry; provide an update on new methods in psychiatric and bipolar research; discuss strategies for shortening the time interval between the end the research training period and the receipt of the first extramural grant support; and to foster relationships with established investigators in the area of bipolar disorder research, who could work over the long term as mentors or consultants. The CDI provides opportunity for participants to engage with other developing investigators in order to facilitate peer support and collaborative research. Presenters at the Institute will range from officials from the National Institute of Mental Health, senior research investigators, and junior faculty scholars.

Applicants who are accepted to participate in the Institute will receive an expense paid trip to Pittsburgh, PA, which is being sponsored in part by a training grant from the National Institute of Mental Health and by the Department of Psychiatry, University of Pittsburgh and the Western Psychiatric Institute and Clinic.

Applicants to the program should be an M.D. and/or Ph.D. at the final year of residency, advance post-doc or junior faculty level of their career trajectory with less than five years as faculty. Applicants should also possess an interest in mental health research in the area of bipolar disorder. For consideration to participate in the 2007 Career Development Institute for Bipolar Disorder and for further details, please visit our Website at [www.cdibipolar.org](http://www.cdibipolar.org) and complete the application and instructions there. All completed application materials must be received no later than January 8, 2007.

**Conflict of Interest Disclosure Policy for Council, Ethics and  
Program Committees**  
**Implemented 12/1/2006**

*Based on recommendations from the Ethics Committee Council approved the following policy for the disclosure and management of potential conflicts of interest for members of Council, the Ethics Committee, and the Program Committee. This new policy is being implemented effective December 1, 2006 for Council and with the 2007 Ethics Committee and Program Committee members.*

The ACNP Conflict of Interest Policy, revised and ratified by Council in 1990, specifies that a violation has occurred if any action is taken which might result in or create the appearance of:

- a. giving preferential treatment to any organization or person;
- b. using one's office for personal gain;
- c. losing complete impartiality or independence; or
- d. affecting adversely the confidence of the public in the American College of Neuropsychopharmacology.

All members of ACNP Council, Ethics Committee and Program Committee will be required to disclose any of the following relationships relating to:

- Member of Board of Directors
- Equity Ownership/Partial Ownership or Owner of Company should be disclosed if:
  1. The equity is in a company that has relevance to official ACNP matters or that creates a potential COI for the individual.
  2. The equity is held in an account in which the individual can exercise control over when/if stock is bought and sold. Equity that is held in diversified mutual funds, trusts over which the individual has no control, etc. should not require disclosure.
  3. The equity has a value of \$10,000 or greater on the date the disclosures are made each year.

- Speaker/Speakers' Bureaus for a Company
- Consultancies
- Patents
- Any other honoraria or payments
- Grants
- Any financial relationships of a spouse or dependent child, if known

All members of ACNP Council, Ethics Committee and Program Committee will be required to complete a Disclosure Statement that will be submitted to the Ethics Committee Chair. The Ethics Committee Chair will then provide copies as follows:

- For Program Committee members copies of the disclosure statements will be provided to the Program Committee Chair, the ACNP Secretary, and the Executive Director.
- For Ethics Committee members copies of the disclosure statements will be provided to the Ethics Committee Chair, the ACNP Secretary, and the Executive Director.
- For Council members copies of the disclosure statements will be provided to the President, ACNP Secretary, and the Executive Director.

Before each meeting of these respective bodies the people identified above who have copies of the Disclosure Statements should review them and assume responsibility for ensuring that during the meeting any discussions and/or votes have been preceded with recusals of members with potential conflicts. In any specific instance, the member identified as having a potential conflict of interest may rebut the presumption of conflict, but the decision regarding that member's participation in the discussion or the vote will be decided by the remaining members of the committee or Council.

## 2006 in Review

Alan Frazer  
Secretary



My first year as Secretary has been much more time-consuming than I thought it would be. I anticipated that Ronnie Wilkins and his staff would handle at least 90% of the responsibilities that Oakley had assumed – and this has been so. What I did not realize was the magnitude of the scope of activities of the ACNP such that taking responsibility for even 10% becomes substantial.

The dissemination of high quality science has always been, and

likely will always be, the primary reason for our existence, with our annual meeting being a key venue for this. With this in mind, I asked for permission to establish a task force that would assist in developing a questionnaire for our members that would address all key components of our meeting, e.g., location, content, ambience, etc. The task force members are Ellen Frank, Michael Green, Terry Goldberg, Phillip Harvey, and Richard Keefe. It was decided early on that it would be wise to engage a professional group to help with this. After developing a request for proposal (RFP) and interviewing several companies, the ACNP hired Innovation Management, based in North Carolina, to assist us with this project. They will be holding focus groups with randomly selected, but diverse, members at our upcoming meeting. Information obtained from this process will be used, in part, to develop a survey that will be distributed electronically to all members in February/March. The results of the survey will be made available to the membership and will be used by Council when they make important decisions about our meeting. I am quite pleased at the way this project has been developing and consider the establishment of this task force a key component of my responsibility as Secretary to make certain that Council has received valid and complete information from the membership to use when making their decisions.

The second issue that deserves brief mention was the establishment of a second task force, composed of past Presidents of the ACNP, to begin planning for our 50<sup>th</sup> Anniversary Meeting in 2011. Its members are Huda Akil, Biff Bunney, Dave Kupfer, Herb Meltzer, and Chuck O'Brien. We will hold our first meeting at the upcoming annual meeting in Hollywood, Florida. The only decision made to date is to eliminate Teaching Day in 2011 and substitute special events for the Anniversary Meeting. We welcome receiving any ideas you may have about this and will keep you informed as more planning occurs.

In conclusion, this first year has been eventful and I am looking forward to learning the views of our members about our annual meeting.

## ACNP Strategic Plan Report Preview

Ronnie Wilkins

In 2004, Council spent much of the year developing a strategic plan for the ACNP. We announced it at the annual meeting that year and began implementation in 2005. As we approach the end of our second year of operation with the plan guiding us, I can report that the results have been very positive. Following the annual meeting this year we will prepare a detailed report for you on progress and accomplishments, but I thought this would be a good opportunity to give you a preview and to hit a few highpoints.

In our strategic plan we set goals that relate to the annual meeting; the journal; the role of the ACNP as a credible source of scientific information; our collaborative relationships with advocacy groups, government, academia, and industry; membership renewal; and organizational effectiveness. Council also took note of mega-issues that relate to every goal and objective of the College and must be top of mind as we go forward.

Perhaps the most important impact of the strategic plan thus far has been in relationship to the goal of organizational effectiveness and the mega-issue of our relationship to the pharmaceutical industry. Council made the decision as a part of the strategic planning process to spend the majority of its time on strategic issues, to give clear charges to the various committees of the College, to listen to the committee reports and recommendations, and to empower committees to do the work necessary to achieve their objectives. Since making that commitment Council has been exemplary in keeping it, and as a result our committees have taken initiative and have accomplished many of the objectives with impressive results. At the meeting next month you will hear the Publications Committee report on our new *Neuropsychopharmacology Reviews* publication, along with other work they have done to negotiate a contract extension with our journal publisher and the search for a new editor. The Liaison Committee will announce our new corporate code of conduct, developed with a grant from the Association of American Medical Colleges and the Office of Research Integrity. The Liaison Committee has also developed a document on roles and responsibilities of supporting corporations to provide more guidance for our corporate colleagues for their interaction with the College, and a position statement on clinical trials registries. The Public Information Committee has been pro-active in identifying press releases around journal articles and meeting presentations that have been widely covered in the press and have helped to accomplish the educational goals of the College. This year the Human Research Committee sponsored a meeting in Washington on the need for an improved system of post-marketing drug surveillance. This list of committee accomplishments could go on and on, and it is safe to say that this change in governance style by Council has been instrumental in increasing the amount of committee activity.

The mega-issue of our relationship to the pharmaceutical industry permeates almost every goal and activity of the College. We are subject to intense scrutiny, some of which is fair and much of which is not, but is a reality just the same. As we have moved forward with our strategic plan we have taken a number of steps that have codified our relationship with our supporting corporations, that have strengthened the firewalls that protect the College and our supporting corporations from the perception of influence, and that have changed the financial model of the College by reducing the percentage of revenue from industry. We should compliment our supporting corporations in this regard. They have been completely supportive and cooperative in these efforts, which is a testament to their high regard for the ACNP and to their own commitment to these same core values.

As we all know, it is nice to see a plan come together and work in the way it was intended. The ACNP strategic plan has been, in my opinion, very successful in these past two years. It has been a rewarding experience to be a part of it and I look forward to its continued successful implementation.

## Upcoming Meetings

### 8th International Conference on AD/PD

March 14 - 18, 2007  
Salzburg, Austria  
Secretariat:  
Kenes International  
Tel: +41 22 908 0488  
Fax: +41 22 732 2850  
[www.kenes.com/adpd](http://www.kenes.com/adpd)  
[adpd@kenes.com](mailto:adpd@kenes.com)



### 62nd Annual Convention Society of Biological Psychiatry

May 17th-19th, 2007  
Westin Horton Plaza  
San Diego, CA  
[Peterson.maggie@mayo.edu](mailto:Peterson.maggie@mayo.edu)  
<http://www.sobp.org/>

### APA

May 19-24, 2007  
2007 Annual Meeting  
San Diego, CA  
<http://www.psych.org/>  
[apa@psych.org](mailto:apa@psych.org)

### CCNP

June 15-18, 2007  
30th Annual Meeting  
Banff, Alberta  
[www.ccnpc.ca](http://www.ccnpc.ca)

### 20th ECNP Congress

October 13 - 17, 2007  
Vienna, Austria  
[ecnp2007@iceo.be](mailto:ecnp2007@iceo.be)

### ACNP Annual Meeting

December 9-13, 2007  
Boca Raton Resort and Club  
Boca Raton, FL  
[www.acnp.org](http://www.acnp.org)  
[acnp@acnp.org](mailto:acnp@acnp.org)

### ACNP Annual Meeting

December 7-11, 2008  
The Fairmont Scottsdale Princess  
Scottsdale, AZ  
[www.acnp.org](http://www.acnp.org)  
[acnp@acnp.org](mailto:acnp@acnp.org)

# See you in Hollywood, FL!



## ACNP Executive Office

545 Mainstream Drive, Suite 110

Nashville, TN 37228-1201

**Main Phone: 615-324-2360**

**Fax: 615-324-2361**

Staff	Direct Telephone Numbers
Ronnie Wilkins	615-324-2375
Kathy Latimer	615-324-2377
Jennifer Mahar	615-324-2371
Jerry Maher	615-324-2373
John Marshall	615-324-2378
Sarah Timm	615-324-2374
Kay White	615-324-2379

To list an event or make a comment regarding the Bulletin please email Jennifer Mahar at [jmahar@acnp.org](mailto:jmahar@acnp.org)



**American College of  
Neuropsychopharmacology**

545 Mainstream Drive, Suite 110  
Nashville TN 37228-1201

Tel: 615-324-2360  
Fax: 615-324-2361  
E-mail: [acnp@acnp.org](mailto:acnp@acnp.org)

**We're on the web  
[www.acnp.org](http://www.acnp.org)**

**Westin Diplomat: <http://www.diplomatresort.com>**

